Olav Engebraaten

3.8k citations

87 papers · 2.7k indexed · h-index 29

Cancer Research top 2%
- Breast Cancer Treatment Studies 13
- Cancer Genomics and Diagnostics 10
Oncology top 5%
- HER2/EGFR in Cancer Research 11
- Cancer Cells and Metastasis 9
- Cancer Treatment and Pharmacology 8
Immunology and Allergy top 5%
Genetics top 5%
Molecular Biology top 5%
- RNA Interference and Gene Delivery 7
Radiology, Nuclear Medicine and Imaging
- Monoclonal and Polyclonal Antibodies Research 12
- MRI in cancer diagnosis 7

Co-authors: Øystein Fodstad Rolf Bjerkvig Gunhild M. Mælandsmo Anne‐Lise Børresen‐Dale Ole Didrik Lærum Paal‐Henning Pedersen Hans Kristian Moen Vollan Geir Olav Hjortland
Cited by: Cancer Research Oncology Immunology and Allergy
Partner nations: Norway United States United Kingdom

In The Last Decade

Olav Engebraaten

85 papers receiving 2.6k citations

Peers

Countries citing papers authored by Olav Engebraaten

Since Specialization

Citations

This map shows the geographic impact of Olav Engebraaten's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olav Engebraaten with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olav Engebraaten more than expected).

Fields of papers citing papers by Olav Engebraaten

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olav Engebraaten. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olav Engebraaten. The network helps show where Olav Engebraaten may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Olav Engebraaten, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Olav Engebraaten Line = papers co-authored together Olav Engebraaten links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	High mid-treatment tumour RNA disruption in patients with HER2-negative breast cancer is associated with improved disease-free survival after neoadjuvant chemotherapy Amadeo M. Parissenti,Laura B. Pritzker,Maria Aanesland Dahle,Hedda von der Lippe Gythfeldt,Twinkle Masilamani,Gabriel Thériault,Renée St-Onge,Lavina D’costa,Ole Christian Lingjærde,Mads H. Haugen,Olav Engebraaten	2025	0
2	An integrated omics approach highlights how epigenetic events can explain and predict response to neoadjuvant chemotherapy and bevacizumab in breast cancer Thomas Fleischer,Mads H. Haugen,Jørgen Ankill,Laxmi Silwal‐Pandit,Anne‐Lise Børresen‐Dale,Ingrid Hedenfalk,Thomas Hatschek,Jörg Tost,Olav Engebraaten,Vessela N. Kristensen	2024	3
3	Liver X receptors induce antiproliferative effects in basal‐like breast cancer Mads H. Haugen,Hedda von der Lippe Gythfeldt,Eivind Valen Egeland,Lisa Svartdal Normann,Abhilash Pandya,Lise‐Lotte Vedin,Siri Juell,Ellen Tenstad,Geir Frode Øy,Alexandr Kristian,Elisabetta Marangoni,Thérese Sørlie,Knut R. Steffensen,Gunhild M. Mælandsmo,Olav Engebraaten	2023	2
4	Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer Kristi Krüger,Laxmi Silwal‐Pandit,Elisabeth Wik,Oddbjørn Straume,Ingunn M. Stefansson,Elin Borgen,Øystein Garred,Bjørn Naume,Olav Engebraaten,Lars A. Akslen	2021	16
5	Immune phenotype of tumor microenvironment predicts response to bevacizumab in neoadjuvant treatment of ER‐positive breast cancer Hedda von der Lippe Gythfeldt,Tonje G. Lien,Xavier Tekpli,Laxmi Silwal‐Pandit,Elin Borgen,Øystein Garred,Helle Kristine Skjerven,Ellen Schlichting,Steinar Lundgren,Erik Wist,Bjørn Naume,Vessela N. Kristensen,Anne‐Lise Børresen‐Dale,Ole Christian Lingjærde,Olav Engebraaten	2020	14
6	Toward Personalized Computer Simulation of Breast Cancer Treatment: A Multiscale Pharmacokinetic and Pharmacodynamic Model Informed by Multitype Patient Data Xiaoran Lai,Oliver Geier,Thomas Fleischer,Øystein Garred,Elin Borgen,Simon W. Funke,Surendra Kumar,Marie E. Rognes,Therese Seierstad,Anne‐Lise Børresen‐Dale,Vessela N. Kristensen,Olav Engebraaten,Alvaro Köhn‐Luque,Arnoldo Frigessi	2019	17
7	Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft Markus Fußer,Anders Øverbye,Abhilash Pandya,Ýrr Mørch,Sven Even Borgos,Wanja Kildal,Sofie Snipstad,Einar Sulheim,Karianne G. Fleten,Hanne A. Askautrud,Olav Engebraaten,Kjersti Flatmark,Tore‐Geir Iversen,Kirsten Sandvig,Tore Skotland,Gunhild M. Mælandsmo	2018	43
8	Dynamic 2-Deoxy-2-[18F]Fluoro-D-Glucose Positron Emission Tomography for Chemotherapy Response Monitoring of Breast Cancer Xenografts Alexandr Kristian,Jon Erik Holtedahl,Turid Torheim,Cecilia Marie Futsæther,Eivor Hernes,Olav Engebraaten,Gunhild M. Mælandsmo,Eirik Malinen	2016	5
9	Phase I trial of EpCAM-targeting immunotoxin MOC31PE, alone and in combination with cyclosporin Yvonne Andersson,Olav Engebraaten,Siri Juell,Steinar Aamdal,Paal Brunsvig,Øystein Fodstad,Svein Dueland	2015	28
10	Proteomic Characterization of Breast Cancer Xenografts Identifies Early and Late Bevacizumab-Induced Responses and Predicts Effective Drug Combinations Evita M. Lindholm,Marit Krohn,Sergio Iadevaia,Alexandr Kristian,Gordon B. Mills,Gunhild M. Mælandsmo,Olav Engebraaten	2013	28
11	In vivo MRI and histopathological assessment of tumor microenvironment in luminal‐like and basal‐like breast cancer xenografts Else Marie Huuse,Siver Andreas Moestue,Evita M. Lindholm,Tone F. Bathen,Hawa Nalwoga,Kristi Krüger,Anna M. Bofin,Gunhild M. Mælandsmo,Lars A. Akslen,Olav Engebraaten,Ingrid S. Gribbestad	2011	27
12	Molecular profiling and characterization of luminal‐like and basal‐like in vivo breast cancer xenograft models Anna Bergamaschi,Geir Olav Hjortland,Tiziana Triulzi,Thérese Sørlie,Hilde Johnsen,Anne Hansen Ree,Hege G. Russnes,S Trønnes,Gunhild M. Mælandsmo,Øystein Fodstad,Anne‐Lise Børresen‐Dale,Olav Engebraaten	2009	86
13	Synergistic anti-cancer effects of immunotoxin and cyclosporin in vitro and in vivo Yvonne Andersson,Olav Engebraaten,Øystein Fodstad	2009	33
14	Combined treatment with Ad‐hTRAIL and DTIC or SAHA is associated with increased mitochondrial‐mediated apoptosis in human melanoma cell lines Trine Lillehammer,Birgit Engesæter,Lina Prasmickaite,Gunhild M. Mælandsmo,Øystein Fodstad,Olav Engebraaten	2007	46
15	Immunotoxin treatment targeted to the high-molecular-weight melanoma—associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme Geir Olav Hjortland,Solveig Garman-Vik,Siri Juell,Øyvind Edon Olsen,Henry Hirschberg,Øystein Fodstad,Olav Engebraaten	2004	24
16	Expression of extracellular matrix components in a highly infiltrative in vivo glioma model Rupavathana Mahesparan,Tracy‐Ann Read,Morten Lund‐Johansen,Kai Ove Skaftnesmo,Rolf Bjerkvig,Olav Engebraaten	2003	131
17	Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals Olav Engebraaten,Geir Olav Hjortland,Siri Juell,Henry Hirschberg,Øystein Fodstad	2001	29
18	Differential display analysis of breast carcinoma cells enriched by immunomagnetic target cell selection: Gene expression profiles in bone marrow target cells Anne Hansen Ree,Olav Engebraaten,Eivind Hovig,Øystein Fodstad	2001	12
19	Expression of a novel factor in human breast cancer cells with metastatic potential. Anne Hansen Ree,Marianne Tvermyr,Olav Engebraaten,Marianne Rooman,Øystein Røsok,Eivind Hovig,Leonardo A. Meza‐Zepeda,Øyvind S. Bruland,Øystein Fodstad	1999	94
20	散在性悪性黒色腫の発癌におけるpRb/p16/cdk4/サイクリンD1経路の関与 Gunhild M. Mælandsmo,Viví Ann Flørenes,Eivind Hovig,Tove Øyjord,Olav Engebraaten,Ruth Holm,Borresen A-L,Øystein Fodstad	1996	4

About Olav Engebraaten

Olav Engebraaten is a scholar working on Cancer Research, Oncology and Immunology and Allergy, having authored 87 papers that have together received 2.7k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (13 papers), Monoclonal and Polyclonal Antibodies Research (12 papers), HER2/EGFR in Cancer Research (11 papers), Cancer Genomics and Diagnostics (10 papers), Cancer Cells and Metastasis (9 papers), Cancer Treatment and Pharmacology (8 papers), MRI in cancer diagnosis (7 papers) and RNA Interference and Gene Delivery (7 papers). The work is most often cited by research in Cancer Research (700 citations), Oncology (925 citations) and Immunology and Allergy (187 citations). Olav Engebraaten has collaborated with scholars based in Norway, United States and United Kingdom. Frequent co-authors include Øystein Fodstad, Rolf Bjerkvig, Gunhild M. Mælandsmo, Anne‐Lise Børresen‐Dale, Ole Didrik Lærum, Paal‐Henning Pedersen, Hans Kristian Moen Vollan, Geir Olav Hjortland, Morten Lund‐Johansen and Eivind Hovig.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact